Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nesvacumab + aflibercept
- Development stage
- Unknown
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravitreal
01
Overview
Nesvacumab + aflibercept is a fixed-dose combination of two monoclonal antibodies administered as a single co-formulated intravitreal injection. Nesvacumab is an anti-angiopoietin-2 (Ang2) antibody, while aflibercept is an anti-vascular endothelial growth factor (VEGF) agent. The combination was developed to target both Ang2 and VEGF pathways, which are implicated in pathological ocular neovascularization and increased vascular permeability seen in diseases such as neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Clinical studies aimed to determine if dual inhibition would provide superior efficacy over VEGF inhibition alone. However, phase 2 trials found no significant additional benefit in visual acuity or anatomical outcomes compared to aflibercept monotherapy[1][3][4][6][8].
- Other names
- nesvacumab + aflibercept
02
Targets
PGF (Placental Growth Factor)VEGFA (Vascular endothelial growth factor A)VEGFB (Vascular endothelial growth factor B)ANGPT2 (Angiopoietin-2)
Beyond the preview
Go deeper on nesvacumab + aflibercept.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nesvacumab + aflibercept.